Comparison · NCT00853307-sae
Alisertib 50 mg (Platinum-Refractory) vs Alisertib 50 mg (Platinum-Resistant): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Alisertib 50 mg (Platinum-Refractory) vs Alisertib 50 mg (Platinum-Resistant): serious adverse events. Trial comparisons, record NCT00853307-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00853307-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.3 | 0.903 | wilson | |
| Risk in group 2 | 0.28 | 0.143 | 0.476 | wilson | |
| Risk difference, group 1 minus group 2 | 0.387 | -0.029 | 0.66 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.38 | 1.02 | 5.55 | log | |
| Odds ratio, group 1 over group 2 | 5.14 | 0.763 | 34.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Alisertib 50 mg (Platinum-Refractory) than on Alisertib 50 mg (Platinum-Resistant) | 2.59 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Alisertib 50 mg (Platinum-Refractory) | Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).Platinum-refractory disease is characterized by a lack of response, progression, or recurrence of disease during a course of platinum-based therapy. | 4 | 6 | EG000 |
| Group 2 | Alisertib 50 mg (Platinum-Resistant) | Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles). Platinum-resistant disease is characterized by progression or recurrence of malignant disease within 6 months after completion of a platinum-based regimen. | 7 | 25 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- First dose of study drug to 30 past last dose of study drug (Up to18.9 Months)
Source ClinicalTrials.gov
Trial
- Title
- MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
- NCT number
- NCT00853307
- Phases
- PHASE2
- Conditions
- Ovarian Carcinoma
- Interventions
- Alisertib
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Results first posted
- 2018-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00853307?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00853307-sae